THE SANOFI MAKEOVER IS IN PROCESS (WSJ MAY 3, 2013). Facing the Patent Cliff on a whopping 30% of their products in 2008, or nearly €800 M, today this has almost zeroed out. As part of the remake it adopted outsourcing and in-licensing (at last), took up an interest in rare diseases (the low hanging fruit are long gone), animal health, consumer medicine, and (of course) sales in emerging markets. Extreme pain can prompt even the most staid groups to take drastic steps to avoid a face-plant.
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022